Go to projects









M€ Budget




Immune-mediated Inflammatory Diseases (IMIDs) are a group of diseases caused by inappropriate activation of the immune system in cells and organs. They are relatively common and affect up to 7% of the general population, being the third most common type of disease in developed countries. In the DoCTIS project, we focus on six of the most frequent IMIDs in our society: rheumatoid arthritis (RA), psoriasis (PsA), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC) and systemic lupus erythematosus (SLE). In these six diseases, chronic activation of the powerful immune system ultimately affects the functionality of many tissues and organs, such as the joints in RA and PsA or the gut in CD and UC. This clearly reduces the quality of life of many patients, as well as increases the risk of other diseases and shortens life expectancy.

Challenge | Doctis

The last 20 years have seen a breakthrough in the development of therapies to treat IMIDs. These therapies have been an improvement over previous drugs, helping reduce the impact on a significant percentage of patients. However, many other patients do not respond adequately to these new therapies. Moreover, in many cases, these new therapies eventually lose efficacy and must be discontinued. These therapies are expensive and have become a major burden on European healthcare systems.

Solution | Doctis

The DoCTIS project is designed to address this major health problem in IMIDs. To do this, we will identify new combinations of existing drugs that enhance the effect of each other. This combinatorial effect will have many beneficial aspects for IMID patients: it will reduce disease activity to remission (i.e. no symptoms), it will reduce the dose of the drugs (and thus the risk of toxicity) and, finally, it will reduce the likelihood of becoming resistant to therapy.

Outcome | Doctis

The DoCTIS project will integrate different experts from clinical, biological, computational and epidemiological fields. These experts will collaborate to generate and analyse high-throughput data generated from IMID patients, as well as animal models of the disease, to identify new drug combinations that are highly effective.

Laura Sesma

“Within the realm of IMIDs, the DoCTIS project emerges as a beacon of hope. Through the strategic identification of synergistic drug combinations, we aim to revolutionize treatment approaches”

Laura Sesma

Team leader expert in European Programmes in the Health Area

Team involved

  • Laura Sesma

    Laura Sesma

    Pamplona Office

    Team leader expert in European Programmes in the Health Area

  • Carla Sala

    Carla Sala

    Valencia Office

    Dissemination and Communication in European Projects



It's not about the sector, it's the about project

The important thing is not to keep moving, but rather to know in which direction to go. Our 37% success rate proves that we know how to guide our clients.

Areas of specialisation

How can we help you?

Our compass is our clients; our mission is to solve their problems, guiding them so that innovation becomes their key to competitiveness.

Get to know our services